Navigation Links
GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
Date:3/10/2008

New study results also demonstrate the longest duration of consistently

high antibody levels shown by a cervical cancer vaccine

TAMPA, Fla., March 10 /PRNewswire-FirstCall/ -- New data demonstrate that GlaxoSmithKline's (NYSE: GSK) cervical cancer candidate vaccine, CERVARIX(R) provides significant protection for women against the four most common cancer- causing human papillomavirus types for nearly six and a half years, the longest duration of protection reported to date. Over this time, the cervical cancer candidate vaccine showed 100 percent efficacy in preventing precancerous lesions due to cancer-causing virus types 16 and 18 and also provided substantial protection against infection caused by virus types 31 and 45.

These data show that virtually 100 percent of women in the study, 15-25 years of age, maintained high levels of antibodies against both virus types 16 and 18 at every time point for nearly six and half years. This signifies the longest duration of consistently high antibody levels demonstrated by a cervical cancer vaccine. Antibody levels remained several times higher than natural infection levels over the extended period of time.

"With this trial, we continue to see high levels of antibodies that lasted over time in virtually all women studied, which is critical for the prevention of cervical cancer," said Diane Harper, MD, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, NH. "These data are remarkable as they show the potential for this cervical cancer vaccine to protect women over the long term."

The study also confirmed substantial cross-protection for nearly six and a half years against incident infection caused by virus types 45 and 31. Specifically, the vaccine showed 78 percent efficacy in preventing incident infection caused by virus type 45, and 60 percent efficacy in preventing incident infection caused by virus type 31.

Virus types 18 and 45 are responsible for a significant percentage of a particularly aggressive and deadly form of cervical cancer known as adenocarcinoma. This type of cervical cancer tends to occur in younger women and is not well detected by routine screening methods.

"We specifically designed our cervical cancer vaccine with the goal of providing long-lasting protection from cervical cancer," said James Tursi, MD, Director of Medical Affairs, North America, GlaxoSmithKline. "These study results are important because women remain at risk for infection with cancer- causing virus types throughout their lives, and long-term protection will be an essential component of a successful vaccination strategy."

The results also include safety data from nearly six and a half years, showing that the candidate vaccine had no meaningful differences between the study groups and had a favorable overall safety profile.

These data were presented today at the Society of Gynecologic Oncologists (SGO) annual meeting in Tampa, FL.

Notes to editors

About the study

This was an extended follow-up (EFU) analysis of women who participated in the initial efficacy study of GSK's cervical cancer candidate vaccine. The initial study was a double-blind, controlled trial of 1,113 young women between 15-25 years of age, randomized to receive three doses of the GSK candidate vaccine for cervical cancer formulated with the AS04 adjuvant system, or three doses of placebo on a 0, 1 and 6 month schedule.

This extended follow-up study looked at study endpoints for 776 women from the same cohort of women for a period of up to 76 months. The trial was conducted in 28 centers in Brazil, Canada and the U.S. and evaluated the efficacy, safety and immunogenicity of GSK's cervical cancer candidate vaccine for the prevention of infection with cancer causing virus types 16 and/or 18, and other cancer-causing virus types, as well as associated Pap smear abnormalities and cervical precancerous lesions. In the extended follow up study, women were evaluated for the presence of human papillomavirus DNA by PCR using cervical samples and annual cervical cytology evaluations were performed. Women were referred for colposcopy following protocol guidelines. Women were also assessed for long-term immunogenicity and safety.

About cervical cancer and its progression

Approximately 100 types of human papillomavirus have been identified to date and, of these, approximately 15 virus types are known to cause cervical cancer. Virus types 16, 18, 45 and 31 are responsible for approximately 80 percent of cervical cancers globally. Infection with cancer-causing virus types can lead to the formation of abnormal cells in the cervix, which, over time, may become precancerous or cancerous. It is a necessary precursor of cervical cancer. Throughout their lifetime, women may be exposed to cancer- causing virus types and are potentially at risk of developing cervical cancer.

Worldwide, more than 500,000 women will be newly diagnosed with cervical cancer and over 280,000 women will die from it each year. In the United States, after breast cancer, cervical cancer is the second leading cause of cancer death in women ages 20 to 39.

About the GSK Cervical Cancer Vaccine

To date, CERVARIX(R) has been approved in 55 countries around the world including the 27 member countries of the European Union, Mexico, Australia, Singapore and the Philippines. Licensing applications have been submitted in 28 additional countries including Japan. GSK also submitted CERVARIX(R) to the World Health Organization (WHO) for prequalification in September 2007.

GSK submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its cervical cancer candidate vaccine in March 2007.

About GlaxoSmithKline

GlaxoSmithKline--one of the world's leading research-based pharmaceutical and healthcare companies--is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, please visit http://www.gsk.com/media.

GSK Biologicals (GSK Bio), one of the world's leading vaccine manufacturers, is headquartered in Rixensart, Belgium, where the majority of GlaxoSmithKline's activities in the field of vaccine research, development and production are conducted. GSK Bio employs more than 1,500 scientists, who are devoted to discovering new vaccines and developing more cost-effective and convenient combination products to prevent infections that cause serious medical problems worldwide. In 2006, GSK Bio distributed more than 1.1 billion doses of vaccines to 169 countries in both the developed and the developing world -- an average of 3 million doses a day. Of those vaccine doses, approximately 136 million were doses of combination pediatric vaccines which protect the world's children with up to six diseases in one vaccine.

Inquiries:

US Media Inquiries: Liad Diamond (919) 483 2839

European Analyst/Investor Inquiries: David Mawdsley +44 20 8047 5564

Sally Ferguson +44 20 8047 5543

US Analyst/Investor Inquiries: Frank Murdolo (215) 751 7002

Tom Curry (215) 751 5419

References:

(1) Harper D, Gall S, et al. HPV-007 Efficacy Abstract. "Sustained

Immunogenicity and high efficacy against HPV-16/18 related cervical

neoplasia: Long-term follow-up through 6.4 years in women vaccinated

with CERVARIX (GSKS HPV 16/18 AS04 Candidate vaccine)" To be

presented at: SGO's Annual Meeting on Women's Cancer. March 10, 2008

Tampa Convention Center.

(2) Wieting S., et al. HPV-013 Month 18 Extension Abstract. Presented at

the European Society of Paediatric Infectious Diseases (ESPID) annual

meeting on 2-4 May 2007

(3) GSK Data on File

(4) Schuind A. HPV-007 Final Analysis. To be presented at: SGO's Annual

Meeting on Women's Cancer. March 10, 2008

(5) Bulk S, Berkhof J, Bulkmans NW, et al. Preferential risk of HPV16 for

squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix

compared to women with normal cytology in The Netherlands. Br J

Cancer. 2006;94:171-175.

(6) Liu S, Semenciw R, et al. Cervical cancer: the increasing incidence

of adenocarcinoma and adenosquamous carcinoma in younger women. CMAJ

2001; 164: 1151-1152.

(7) Harper DM, Franco EL et al. Sustained efficacy up to 4.5 years of a

bivalent L1 virus-like particle vaccine against human papillomavirus

types 16 and 18: follow-up from aluminium control trial. The Lancet

2006; 367: 1247-1255.

(8) Gall, S., et al. Sustained Efficacy up to 5.5 years in women

vaccinated with an AS04 Adjuvanted HPV 16/18 L1 VLP Vaccine.

Presented at AACR Medical Meeting. April 17, 2007

(9) Gravitt PE, Jamshidi R. Diagnosis and management of oncogenic

cervical human papillomavirus infection. Infect Dis Clin North Am,

2005; 19:439-458

(10) Munoz N, Bosch FX, de Sanjose S,et al. Epidemiologic classification

of human papillomavirus types associated with cervical cancer. N Engl

J Med 2003; 348: 518-527

(11) Munoz N, Bosch FX, Castellsague X et al. Against which human

papillomavirus types shall we vaccinate and screen? The international

perspective. Int. J. Cancer 2004; 111; 278-285

(12) Harper DM, Franco EL, et al, for the GlaxoSmithKline HPV Vaccine

Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in

prevention of infection with human papillomavirus types 16 and 18 in

young women: a randomized controlled trial. Lancet 2004; 364: 1757-

1765.

(13) Baseman JG, Koutsky LA. The epidemiology of human papillomavirus

infections J Clin Virol 2005; 32 Suppl 1; S16-24

(14) World Health Organization. Initiative for Vaccine Research.

http://www.who.int/vaccine_research/diseases/hpv/en/ Accessed on May

2, 2007

(15) Jemal A, Murray T, Ward E, Sammuels A et al. Cancer Statistics, 2007.

Cancer Journal for Clinicians 2007; 57:43-66.


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
2. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
3. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
6. Northwestern Memorial Study Tests Cancer Drug on Scleroderma Patients
7. ACR Supports American Cancer Society Inclusion of CT Colonography (Virtual Colonoscopy) as Recommended Screening Tool for Colorectal Cancer in New Screening Guidelines
8. Thomson Healthcare Cancer Profiler Used in Study
9. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
10. CMC, Moffitt Partner to Study Cancer
11. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... February 28, 2017 The global  pulse oximeters market  is ... by Grand View Research, Inc. The pulse oximeters market is anticipated to witness ... prevalence of target diseases such as chronic obstructive pulmonary disease (COPD), sleep apnea, ... ... Grand View Research Logo ...
(Date:2/28/2017)... Nordic Nanovector ASA (OSE: NANO) announces its results for the fourth ... the company,s senior management team will take place today at 8:30 ... ... very successful year for Nordic Nanovector. We achieved important milestones with ... candidates and build the foundation of R&D innovation and expertise for ...
(Date:2/27/2017)... Ga., Feb. 27, 2017 Halyard Health, Inc. (NYSE: ... 2016 results and provided its 2017 outlook and related key ... sales were $410 million, a 2 percent increase compared to ... fourth quarter 2016 was $10 million compared to net income ... quarter adjusted net income was $24 million compared to adjusted ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine Coast Health Centre (SCHC), ... Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of a ... the Centre's commitment to innovation in drug rehab and alcohol treatment strategies beyond ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, a ... an upgrade to the company's Yelp listing. Bay Area residents struggling from thinning ... as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as Follicular Unit ...
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination of ... concern over nerve agents and the deadly use of chemical weapons. Many questions exist ... how even small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan ...
(Date:2/26/2017)... ... 2017 , ... This is an extension of airmid’s scope ... ISO/IEC 17025:2005 INAB accredited for Der p 1 (house dust mite allergen) & ... standard that sets out requirements for the technical competence of testing and calibration ...
(Date:2/26/2017)... ... February 26, 2017 , ... LatitudeC ... North America, today announced it would be offering some it’s exclusive product line ... on crafting quality and unique baby clothing/feeding products, will team up with AMAZON ...
Breaking Medicine News(10 mins):